glp 1/gip receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica PDB-101: Molecule of the Month:
Description
Turmeric Extract - Supports Antioxidant Activity*
This review examines the biological mechanisms underlying GLP-1 RA therapy in MASLD/MASH, analyzes the mechanistic distinctions between mono-, dual-, and triple agonists, and synthesizes current clinical evidence supporting their utilization in individuals with this condition.
Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders worldwide
Results Reducing dose frequency does not commensurately reduce weight loss
Example code lists used to identify covariates are included in supplementary table S2
